Clinical Report: Reevaluating Sudden Cardiac Death in HFmrEF/HFpEF

Overview

This report examines findings from a post hoc analysis of the FINEARTS-HF trial, revealing that sudden cardiac death in patients with heart failure with mildly reduced or preserved ejection fraction is often preceded by measurable clinical deterioration.

Background

Sudden cardiac death remains a significant concern in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Understanding the clinical changes that precede these events is crucial for improving risk stratification and management strategies.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

• Patients who experienced sudden death showed modest worsening in New York Heart Association class.
• There was an approximately 8-point decline in Kansas City Cardiomyopathy Questionnaire Total Symptom Score prior to sudden death.
• N-terminal pro–B-type natriuretic peptide levels rose in the months leading up to sudden death.
• Survivors demonstrated improvement in functional status and symptom burden, contrasting with those who died suddenly.
• Patients dying from heart failure-related or other nonsudden cardiovascular causes exhibited similar declines, limiting the specificity of these changes for sudden death risk.
• The study suggests that sudden deaths may occur in the context of subacute clinical worsening.

Clinical Implications

The findings indicate that clinicians should be aware of the potential for measurable clinical deterioration preceding sudden death in HFmrEF/HFpEF patients.

Conclusion

This analysis highlights the need for further understanding of the dynamics surrounding sudden death in heart failure.

Related Resources & Content

1. Conexiant, Sudden Death Trajectories in HFpEF, HFmrEF, 2023 -- Sudden Death Trajectories in HFpEF, HFmrEF
2. Frontiers in Cardiovascular Medicine, Risk stratification for sudden cardiac death in nonischemic dilated cardiomyopathy: a moving target?, 2026 -- Risk stratification for sudden cardiac death in nonischemic dilated cardiomyopathy: a moving target?
3. JAMA Network Open, Heart Failure Trajectories After Guideline-Directed Medical Therapy, 2026 -- Heart Failure Trajectories After Guideline-Directed Medical Therapy
4. Clinical Research in Cardiology, The Prognostic Role of Previous LVEF in Patients with Heart Failure and Mildly Reduced Ejection Fraction, 2024 -- The Prognostic Role of Previous LVEF in Patients with Heart Failure and Mildly Reduced Ejection Fraction
5. European Heart Journal, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, 2023 -- 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
6. New England Journal of Medicine, Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction, 2023 -- Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
7. ScienceDirect, Sudden Death In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: A Pooled Individual Patient-level Analysis Of Five Randomized Clinical Trials, 2024 -- Sudden Death In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction
8. 2023 ESC Focused Update on Heart Failure
9. FINEARTS-HF Trial Overview
10. Sudden Death In Heart Failure With Mildly Reduced Or Preserved Ejection Fraction: A Pooled Individual Patient-level Analysis Of Five Randomized Clinical Trials - ScienceDirect